Mainz Current Deferred Revenue from 2010 to 2024

MYNZ Stock  USD 0.23  0.02  9.52%   
Mainz Biomed Current Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Current Deferred Revenue will likely drop to about 94.1 K in 2024. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2010-12-31
Previous Quarter
138.9 K
Current Value
94.1 K
Quarterly Volatility
75 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mainz Biomed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mainz Biomed's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 1.1 M or Interest Expense of 419.9 K, as well as many indicators such as Price To Sales Ratio of 19.99, Dividend Yield of 0.0 or PTB Ratio of 6.09. Mainz financial statements analysis is a perfect complement when working with Mainz Biomed Valuation or Volatility modules.
  
Check out the analysis of Mainz Biomed Correlation against competitors.

Latest Mainz Biomed's Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of Mainz Biomed BV over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Mainz Biomed's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mainz Biomed's overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

Mainz Current Deferred Revenue Regression Statistics

Arithmetic Mean43,890
Geometric Mean7,215
Coefficient Of Variation170.99
Mean Deviation60,838
Median2,500
Standard Deviation75,048
Sample Variance5.6B
Range197.9K
R-Value0.69
Mean Square Error3.2B
R-Squared0.47
Significance0
Slope11,532
Total Sum of Squares78.8B

Mainz Current Deferred Revenue History

202494.1 K
2023138.9 K
2021199.4 K
2020 1508.0

About Mainz Biomed Financial Statements

Mainz Biomed investors use historical fundamental indicators, such as Mainz Biomed's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Mainz Biomed. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue138.9 K94.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Mainz Stock Analysis

When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.